Vaccination against meningococcal disease starts for teens aged 14 to 18 This spring, about 860,000 young people in the Netherlands will receive an invitation for a vaccination against meningococcal disease.
Summary International Expert Meeting on breast implant-associated lymphoma On November 19th 2018, RIVM organised an international expert meeting on a rare type of lymphoma that is associated with breast implants.
Vaccination schedule for babies reviewed after introduction whooping cough vaccination for pregnant women Whooping cough is a dangerous disease for new born, unvaccinated babies. Starting at the end of 2019, the whooping cough vaccination will be offered nationwide to pregnant women.
Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).
The Dutch Diet is slightly healthier Recent years show a cautious improvement in the Dutch diet. The Dutch have started to eat more fruit and it seems to be heading in the right direction with vegetables.
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Teen vaccination against meningococcal disease starts From mid-September, young people born between 1 May and 31 December 2004 will receive an invitation for a vaccination against meningococcal disease.
Vaccination rate again drops slightly, HPV vaccination rate drops considerably The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.
First products Dutch Public Health Foresight study available in English In 2017, RIVM launched a Trend Scenario, as well as three thematic reports about the future demand for health care, technology and wider determinants of health.
Trend scenario PHF- 2018 identifies societal challenges for the future If historical trends continue unchanged, dementia will be the leading cause of disease burden in 2040 and the main cause of death.